Nuo Therapeutics (Nuo Therapeutics) Days Payable : 885.79 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Days Payable?

Nuo Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $0.40 Mil. Nuo Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.04 Mil. Hence, Nuo Therapeutics's Days Payable for the three months ended in Dec. 2023 was 885.79.

The historical rank and industry rank for Nuo Therapeutics's Days Payable or its related term are showing as below:

AURX' s Days Payable Range Over the Past 10 Years
Min: 67.46 Med: 914.74 Max: 8884.87
Current: 1200.7

During the past 13 years, Nuo Therapeutics's highest Days Payable was 8884.87. The lowest was 67.46. And the median was 914.74.

AURX's Days Payable is ranked better than
86.13% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs AURX: 1200.70

Nuo Therapeutics's Days Payable declined from Dec. 2022 (2,569.04) to Dec. 2023 (885.79). It may suggest that Nuo Therapeutics accelerated paying its suppliers.

Nuo Therapeutics Days Payable Historical Data

The historical data trend for Nuo Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Days Payable Chart

Nuo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

1,532.04

8,884.87

1,139.55

Nuo Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															2,569.04	3,759.50	1,966.44	707.19	885.79

Competitive Comparison of Nuo Therapeutics's Days Payable

For the Biotechnology subindustry, Nuo Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Days Payable falls into.

Nuo Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nuo Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.398	+	0.395)	/	2 )	/	0.127	*	365
=	0.3965					/	0.127	*	365
=	1,139.55

Nuo Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.401	+	0.395)	/	2 )	/	0.041	*	365 / 4
=	0.398					/	0.041	*	365 / 4
=	885.79

Nuo Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuo Therapeutics (Nuo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

8285 El Rio, Suite 190, Houston, TX, USA, 77054

Website

https://www.nuot.com

Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.

Executives

Charles E Sheedy	10 percent owner	TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden	director, officer: CEO, CFO	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky	director	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer	director
Paul Mintz	director	C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen	officer: CSO	11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman	director	3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer	officer: CHIEF COMMERCIAL OFFICER	C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross	officer: SEE REMARKS	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc	10 percent owner, other: May be part of a 13(d) group	C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr	10 percent owner, other: May be part of a 13(d) group	315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke	10 percent owner, other: May be part of a 13(d) group	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del	director	C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark	10 percent owner, other: May be part of a 13(d) group	C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713